INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|---|
Oct. 12, 2018 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Jun. 30, 2024 |
Jun. 30, 2023 |
|
| Intellectual Property [Member] | |||||
| Amortization expense | $ 295 | $ 294 | $ 589 | $ 589 | |
| Accumulated amortization | $ 6,762 | $ 6,762 | |||
| Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member] | |||||
| Patent acquired | $ 15,200 | ||||
| Estimated useful lives | 13 years | ||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|